Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Accured Expenses (2023 - 2025)

Monte Rosa Therapeutics' Change in Accured Expenses history spans 3 years, with the latest figure at $8.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 136.27% year-over-year to $8.7 million; the TTM value through Dec 2025 reached $7.9 million, up 87.67%, while the annual FY2025 figure was $7.9 million, 87.67% up from the prior year.
  • Change in Accured Expenses reached $8.7 million in Q4 2025 per GLUE's latest filing, up from $4.2 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.7 million in Q4 2025 to a low of -$3.9 million in Q1 2024.
  • Average Change in Accured Expenses over 3 years is $1.3 million, with a median of $2.2 million recorded in 2024.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 186.81% in 2024, then tumbled 220.89% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at $1.3 million in 2023, then surged by 186.81% to $3.7 million in 2024, then soared by 136.27% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Change in Accured Expenses are $8.7 million (Q4 2025), $4.2 million (Q3 2025), and -$2.5 million (Q2 2025).